The trial was not created to assess efficacy of the vaccine, so it is not possible to say whether the antibody responses induced by the vaccine, called BBIBP-CorV, are sufficient to protect people from SARS-CoV-2 infection.
Zheng Zhongwei, head of China's vaccine development task force, said China's annual capacity to make COVID-19 vaccines was expected to reach 610 million doses this year and one billion doses by 2021.
The jab was developed by the Vector Institute in Siberia and completed early-stage human trials last month. The vaccine was registered by Russia's Health Ministry in August. Just like on Wednesday, Putin personally broke the news on national television and said one of his daughters had already been vaccinated, experienced slight side effects and developed antibodies.
Dr Christian Schneider, Interim Chief Scientific Officer at the MHRA, said: "No vaccine will be deployed unless stringent standards have been met through a comprehensive clinical trial programme".
Russian Federation has the world's fourth largest coronavirus caseload with over 1.3 million infections. I can not think of a breakthrough that would be more meaningful to a greater number of people than an effective and safe COVID-19 vaccine.
"The company's revised protocol was approved by the Subject Expert Committee on Thursday", said a source.
Teenage 'computer genius' could become the first millennial saint
Assisi bishop Domenico Sorrentino said this month that a soup kitchen for the poor would be opened in Acutis's honor. Acutis could be the Catholic church's first millennial saint following his beatification on October 10, 2020.
No data has been published in a peer-reviewed journal to date on those trials.
The firm's United Kingdom boss, Ben Osborn, also told the paper that scientists in its main British lab have also unearthed drugs that could provide a potential complete cure for Covid-19, as opposed to merely a preventative vaccine.
A Government spokesperson said: 'The science is clear - vaccines save lives, which is why we are leading a global effort to find a Covid-19 vaccine. Some experts have expressed concern that a major change in the appearance of the corona virus may hinder the making of its effective vaccine.
Some potential vaccines have run into hurdles during Phase 3.
According to the news source, a large-scale human trial of EpiVacCorona is likely to begin in November or December. Johnson & Johnson ordered a temporary halt in its late-stage trial this week after a patient became ill, while AstraZeneca has paused testing in the USA since early September after a patient came down with unexplained neurological symptoms. Around 40,000 volunteers are expected to receive Sputnik V during the phase 3 trial now underway in Russian Federation.